Impact of antihypertensive agents on central systolic blood pressure and augmentation index: A meta-analysis

American Journal of Hypertension

Volumn 29, Issue 4, 2016, Pages 448-457

  McGaughey, Tracey J ^a   Fletcher, Emily A ^a   Shah, Sachin A ^a,b  

^a DAVID GRANT MEDICAL CENTER   (United States)

^b UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Antihypertensive; Augmentation index; Blood pressure; Central blood pressure; Hypertension; meta analysis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MOXONIDINE; NICORANDIL; OMAPATRILAT;

ARTICLE; AUGMENTATION INDEX; CENTRAL SYSTOLIC BLOOD PRESSURE; CROSSOVER PROCEDURE; HUMAN; HYPERTENSION; META ANALYSIS; META ANALYSIS (TOPIC); PREHYPERTENSION; PRESCRIPTION; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ARTERIAL STIFFNESS; BLOOD PRESSURE; COMPLICATION; DRUG EFFECTS; PATHOPHYSIOLOGY; RISK FACTOR; SYSTOLE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; RISK FACTORS; SYSTOLE; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84962552309     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpv134     Document Type: Article

References (88)

1. Centers for Disease Control and Prevention. Vital signs: awareness and treatment of uncontrolled hypertension among adults-United States, 2003-2010. MMWR 2012; 61:703-709.
2. Trudeau L. Central blood pressure as an index of antihypertensive control: determinants and potential value. Can J Cardiol 2014; 30:S23-S28.
3. Cheng HM, Sung SH, Chuang SY, Pearson A, Tufanaru C, White S, Yu WC, Chen CH. Diagnostic performance of a stand-alone central blood pressure monitor: application of central blood pressure in the diagnosis of high blood pressure. Am J Hypertens 2014; 27:382-391.
4. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010; 31:1865-1871.
5. Herbert A, Cruickshank JK, Laurent S, Boutouyrie P. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. Eur Heart J 2014; 35:3122-3133.
6. O'Rourke MF. Pulsatile arterial haemodynamics in hypertension. Aust N Z J Med 1976; 6(Suppl 2):40-48.
7. Horvath IG, Nemeth A, Lenkey Z, Alessandri N, Tufano F, Kis P, Gaszner B, Cziraki A. Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity. J Hypertens 2010; 28:2068-2075.
8. Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001; 38:932-937.
9. Weiss W, Gohlisch C, Harsch-Gladisch C, Tolle M, Zidek W, van der Giet M. Oscillometric estimation of central blood pressure: validation of the Mobil-O-Graph in comparison with the SphygmoCor device. Blood Press Monit 2012; 17:128-131.
10. Narayan O, Casan J, Szarski M, Dart AM, Meredith IT, Cameron JD. Estimation of central aortic blood pressure: a systematic meta-analysis of available techniques. J Hypertens 2014; 32:1727-1740.
11. Protogerou AD, Stergiou GS, Vlachopoulos C, Blacher J, Achimastos A. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: Evidence for specific class-effects of antihypertensive drugs on pressure amplification. Curr Pharm Des 2009; 15:272-289.
12. Manisty CH, Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index. Br J Clin Pharmacol 2013; 75:79-92.
13. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AL, Thurston H, O'Rourke M. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-1225.
14. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151:264-269, W64.
15. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12.
16. Baschiera F, Chang W, Brunel P; AGELESS Study Group. Effects of aliskiren- and ramipril-based treatment on central aortic blood pressure in elderly with systolic hypertension: a substudy of AGELESS. Vasc Health Risk Manag 2014; 10:389-397.
17. Bhagatwala J, Harris RA, Parikh SJ, Zhu H, Huang Y, Kotak I, Seigler N, Pierce GL, Egan BM, Dong Y. Epithelial sodium channel inhibition by amiloride on blood pressure and cardiovascular disease risk in young prehypertensives. J Clin Hypertens (Greenwich) 2014; 16:47-53.
18. Kim EJ, Song WH, Lee JU, Shin MS, Lee S, Kim BO, Hong KS, Han SW, Park CG, Seo HS. Efficacy of losartan and carvedilol on central hemodynamics in hypertensives: a prospective, randomized, open, blinded end point, multicenter study. Hypertens Res 2014; 37:50-56.
19. Peters CD, Kjaergaard KD, Jensen JD, Christensen KL, Strandhave C, Tietze IN, Novosel MK, Bibby BM, Jensen LT, Sloth E, Jespersen B. No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients. Kidney Int 2014; 86:625-637.
20. Agnoletti D, Zhang Y, Borghi C, Blacher J, Safar ME. Effects of antihypertensive drugs on central blood pressure in humans: a preliminary observation. Am J Hypertens 2013; 26:1045-1052.
21. Briasoulis A, Oliva R, Kalaitzidis R, Flynn C, Lazich I, Schlaffer C, Bakris G. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J Clin Hypertens (Greenwich) 2013; 15:473-479.
22. Davis JT, Pasha DN, Khandrika S, Fung MM, Milic M, O'Connor DT. Central hemodynamics in prehypertension: effect of the β-adrenergic antagonist nebivolol. J Clin Hypertens 2013; 15:69-74.
23. Dorresteijn JA, Schrover IM, Visseren FL, Scheffer PG, Oey PL, Danser AH, Spiering W. Differential effects of renin-angiotensin-aldosterone system inhibition, sympathoinhibition and diuretic therapy on endothelial function and blood pressure in obesity-related hypertension: a double-blind, placebo-controlled cross-over trial. J Hypertens 2013; 31:393-403.
24. Eeftinck Schattenkerk DW, van den Bogaard B, Cammenga M, Westerhof BE, Stroes ES, van den Born BJ. Lack of difference between nebivolol/hydrochlorothiazide and metoprolol/hydrochlorothiazide on aortic wave augmentation and central blood pressure. J Hypertens 2013; 31:2447-2454.
25. Ihm SH, Jeon HK, Chae SC, Lim DS, Kim KS, Choi DJ, Ha JW, Kim DS, Kim KH, Cho MC, Baek SH; BELASCO trial investigators, Republic of Korea. Benidipine has effects similar to losartan on the central blood pressure and arterial stiffness in mild to moderate essential hypertension. Chin Med J (Engl) 2013; 126:2021-2028.
26. Kubota Y, Takahashi H, Asai K, Yasutake M, Mizuno K. The influence of a direct renin inhibitor on the central blood pressure. J Nippon Med Sch 2013; 80:25-33.
27. Kwon BJ, Jang SW, Choi KY, Kim DB, Cho EJ, Ihm SH, Youn HJ, Kim JH. Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-naive patients of hypertension. Hypertens Res 2013; 36:79-84.
28. Park S, Rhee MY, Lee SY, Park SW, Jeon D, Kim BW, Kwan J, Choi D. A prospective, randomized, open-label, active-controlled, clinical trial to assess central haemodynamic effects of bisoprolol and atenolol in hypertensive patients. J Hypertens 2013; 31:813-819.
29. Radchenko GD, Sirenko YM, Kushnir SM, Torbas OO, Dobrokhod AS. Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. Vasc Health Risk Manag 2013; 9:535-549.
30. Shahin Y, Cockcroft JR, Chetter IC. Randomized clinical trial of angiotensin- converting enzyme inhibitor, ramipril, in patients with intermittent claudication. Br J Surg 2013; 100:1154-1163.
31. Spanos G, Kalaitzidis R, Karasavvidou D, Pappas K, Siamopoulos KC. Efficacy of aliskiren and valsartan in hypertensive patients with albuminuria: a randomized parallel-group study. J Renin Angiotensin Aldosterone Syst 2013; 14:315-321.
32. Studinger P, Tabak AG, Chen CH, Salvi P, Othmane TE, Torzsa P, Kapocsi J, Fekete BC, Tisler A. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. J Clin Hypertens (Greenwich) 2013; 15:910-917.
33. Takami T, Saito Y. Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial. Drug Des Devel Ther 2013; 7:175-183.
34. Zhou WJ, Wang RY, Li Y, Chen DR, Chen EZ, Zhu DL, Gao PJ. A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. PLoS One 2013; 8:e72102.
35. Frimodt-Moller M, Kamper AL, Strandgaard S, Kreiner S, Nielsen AH. Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease-a randomized trial. PLoS One 2012; 7:e41757.
36. Hayoz D, Zappe DH, Meyer MA, Baek I, Kandra A, Joly MP, Mazzolai L, Haesler E, Periard D. Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen. J Clin Hypertens (Greenwich) 2012; 14:773-778.
37. Kanaoka T, Tamura K, Ohsawa M, Wakui H, Maeda A, Dejima T, Azushima K, Haku S, Mitsuhashi H, Yanagi M, Oshikawa J, Uneda K, Aoki K, Fujikawa T, Toya Y, Uchino K, Umemura S. Effects of aliskiren-based therapy on ambulatory blood pressure profile, central hemodynamics, and arterial stiffness in nondiabetic mild to moderate hypertensive patients. J Clin Hypertens (Greenwich) 2012; 14:522-529.
38. Takenaka T, Seto T, Okayama M, Kojima E, Nodaira Y, Sueyoshi K, Kikuta T, Watanabe Y, Inoue T, Takane H, Ohno Y, Suzuki H. Longterm effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney disease: a randomized controlled study. Am J Nephrol 2012; 35:416-423.
39. Virdis A, Ghiadoni L, Qasem AA, Lorenzini G, Duranti E, Cartoni G, Bruno RM, Bernini G, Taddei S. Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients. Eur Heart J 2012; 33:1530-1538.
40. Vitale C, Marazzi G, Iellamo F, Spoletini I, Dall'Armi V, Fini M, Volterrani M. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. Int J Cardiol 2012; 155:279-284.
41. Williams A, Kenny D, Wilson D, Fagenello G, Nelson M, Dunstan F, Cockcroft J, Stuart G, Fraser AG. Effects of atenolol, perindopril and verapamil on haemodynamic and vascular function in Marfan syndrome - a randomised, double-blind, crossover trial. Eur J Clin Invest 2012; 42:891-899.
42. Ferdinand KC, Pool J, Weitzman R, Purkayastha D, Townsend R. Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. J Clin Hypertens (Greenwich) 2011; 13:366-375.
43. Heffernan KS, Suryadevara R, Patvardhan EA, Mooney P, Karas RH, Kuvin JT. Effect of atenolol vs metoprolol succinate on vascular function in patients with hypertension. Clin Cardiol 2011; 34:39-44.
44. Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, Zilmer M, Eha J. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011; 57:1122-1128.
45. Kandavar R, Higashi Y, Chen W, Blackstock C, Vaughn C, Sukhanov S, Sander GE, Roffidal LE, Delafontaine P, Giles TD. The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension. J Am Soc Hypertens 2011; 5:161-165.
46. Kimura T, Kitamura H, Inoue K, Kawada N, Matsui I, Nagasawa Y, Obi Y, Shinzawa M, Sakata Y, Hamono T, Rakugi H, Isaka Y. Effects of nicorandil on the reduction of BNP levels in patients with chronic kidney disease. Clin Exp Nephrol 2011; 15:854-860.
47. Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Shimada K, Kario K. Association between aldosterone induced by antihypertensive medication and arterial stiffness reduction: the J-CORE study. Atherosclerosis 2011; 215:184-188.
48. Shah NK, Smith SM, Nichols WW, Lo MC, Ashfaq U, Satish P, Johnson JA, Epstein BJ. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study). J Clin Hypertens 2011; 13:917-924.
49. Boutouyrie P, Achouba A, Trunet P, Laurent S; EXPLOR Trialist Group. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension 2010; 55:1314-1322.
50. Doi M, Miyoshi T, Hirohata S, Kamikawa S, Usui S, Kaji Y, Sakane K, Ogawa H, Ninomiya Y, Kusachi S. Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients. Am J Med Sci 2010; 339:433-439.
51. Kinouchi K, Ichihara A, Sakoda M, Kurauchi-Mito A, Itoh H. Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. Hypertens Res 2009; 32:1143-1147.
52. Mackenzie IS, McEniery CM, Dhakam Z, Brown MJ, Cockcroft JR, Wilkinson IB. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54:409-413.
53. Matsui Y, Eguchi K, O'Rourke MF, Ishikawa J, Miyashita H, Shimada K, Kario K. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009; 54:716-723.
54. Palombo C, Malshi E, Morizzo C, Rakebrandt F, Corretti V, Santini F, Fraser AG, Kozakova M. Arterial wave reflection during antihypertensive therapy with barnidipine: a 6-month, open-label study using an integrated cardiovascular ultrasound approach in patients with newly diagnosed hypertension. Clin Ther 2009; 31:2873-2885.
55. Ahimastos AA, Dart AM, Lawler A, Blombery PA, Kingwell BA. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. J Hypertens 2008; 26:1037-1042.
56. Alem M, Milia P, Muir S, Lees K, Walters M. Comparison of the effects of diuretics on blood pressure and arterial stiffness in patients with stroke. J Stroke Cerebrovasc Dis 2008; 17:373-377.
57. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26:351-356.
58. Karalliedde J, Smith A, DeAngelis L, Mirenda V, Kandra A, Botha J, Ferber P, Viberti G. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008; 51:1617-1623.
59. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008; 21:663-667.
60. Schneider MP, Delles C, Klingbeil AU, Ludwig M, Kolloch RE, Krekler M, Stumpe KO, Schmieder RE. Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial. J Renin Angiotensin Aldosterone Syst 2008; 9:49-56.
61. Dart AM, Cameron JD, Gatzka CD, Willson K, Liang YL, Berry KL, Wing LM, Reid CM, Ryan P, Beilin LJ, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Morgan TO, West MJ, Kingwell BA. Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the Second Australian National Blood Pressure Trial. Hypertension 2007; 49:1242-1247.
62. Jiang XJ, O'Rourke MF, Zhang YQ, He XY, Liu LS. Superior effect of an angiotensin-converting enzyme inhibitor over a diuretic for reducing aortic systolic pressure. J Hypertens 2007; 25:1095-1099.
63. Dhakam Z, McEniery CM, Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006; 19:214-219.
64. Rajagopalan S, Kariisa M, Dellegrottaglie S, Bard RL, Kehrer C, Matlow S, Daley W, Pitt B, Brook R. Angiotensin receptor blockade improves vascular compliance in healthy normotensive elderly individuals: results from a randomized double-blind placebo-controlled trial. J Clin Hypertens (Greenwich) 2006; 8:783-790.
65. Tsang TS, Barnes ME, Abhayaratna WP, Cha SS, Gersh BJ, Langins AP, Green TD, Bailey KR, Miyasaka Y, Seward JB. Effects of quinapril on left atrial structural remodeling and arterial stiffness. Am J Cardiol 2006; 97:916-920.
66. Davies J, Carr E, Band M, Morris A, Struthers A. Do losartan and atenolol have differential effects on BNP and central haemodynamic parameters? J Renin Angiotensin Aldosterone Syst 2005; 6:151-153.
67. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens 2005; 18:50-55.
68. Mitchell GF, Lacourciere Y, Arnold JM, Dunlap ME, Conlin PR, Izzo JL Jr. Changes in aortic stiffness and augmentation index after acute converting enzyme or vasopeptidase inhibition. Hypertension 2005; 46:1111-1117.
69. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME; REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 2004; 22:1623-1630.
70. London GM, Asmar RG, O'Rourke MF, Safar ME; REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43:92-99.
71. Neal DA, Brown MJ, Wilkinson IB, Byrne CD, Alexander GJ. Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Transplantation 2004; 77:748-750.
72. Deary AJ, Schumann AL, Murfet H, Haydock S, Foo RS, Brown MJ. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond) 2002; 103:493-499.
73. Klingbeil AU, John S, Schneider MP, Jacobi J, Weidinger G, Schmieder RE. AT1-receptor blockade improves augmentation index: a doubleblind, randomized, controlled study. J Hypertens 2002; 20:2423-2428.
74. Mahmud A, Feely J. Effect of angiotensin ii receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens 2002; 15:1092-1095.
75. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002; 15:321-325.
76. Asmar RG, London GM, O'Rourke ME, Mallion JM, Romero R, Rahn KH, Trimarco B, Fitzgerald D, Hedner T, Duprez D, De Leeuw PW, Sever P, Battegay E, Hitzenberger G, de Luca N, Polonia P, Benetos A, Chastang C, Ollivier JP, Safar ME; REASON Project Investigators (pREterax in regression of Arterial Stiffness in a contrOlled double-bliNd Study). Amelioration of arterial properties with a perindopril-indapamide very-low-dose combination. J Hypertens Suppl 2001; 19:S15-S20.
77. Dart AM, Reid CM, McGrath B; Tonometry Study Group. Effects of ACE inhibitor therapy on derived central arterial waveforms in hypertension. Am J Hypertens 2001; 14:804-810.
78. Spratt JC, Webb DJ, Shiels A, Williams B. Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects. J Renin Angiotensin Aldosterone Syst 2001; 2:227-232.
79. Chen CH, Ting CT, Lin SJ, Hsu TL, Yin FC, Siu CO, Chou P, Wang SP, Chang MS. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension 1995; 25:1034-1041.
80. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90:2786-2796.
81. Guerin AP, Pannier BM, Marchais SJ, Metivier F, Safar M, London GM. Effects of antihypertensive agents on carotid pulse contour in humans. J Hum Hypertens 1992; 6(Suppl 2):S37-S40.
82. Sleight P, Salim Y, Pogue J, Tsuyuki R, Diaz R, Probstfield, J. Heart Outcomes Prevention Evaluation (HOPE) Study. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358:2130-2131.
83. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553.
84. Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev 2012;11:3-80.
85. Larochelle P, Tobe SW, Lacourciere Y. β-Blockers in hypertension: studies and meta-analyses over the years. Can J Cardiol 2014; 30:S16-S22.
86. Lopez-Sendon J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C; Task ForceOn Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25:1341-1362.
87. Messerli FH, Grossman E, Goldbourt U. Are β-Blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279:1903-1907.
88. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.